文章摘要
从肠道微生态的角度探讨免疫疗法在癌症治疗中的作用
Explore the role of immunotherapy in cancer treatment from the perspective of intestinal microecology
投稿时间:2020-12-29  修订日期:2021-01-12
DOI:
中文关键词: 肠道菌群 癌症 免疫疗法
英文关键词: intestinal flora  cancer  immunotherapy
基金项目:] 国家自然科学基金资助课题(81360345),甘肃中医药管理局自然科学基金资助课题(GZK-2016-11)
作者单位邮编
岳晓华 甘肃中医药大学 730000
张小平 甘肃中医药大学 730000
王碧莹 甘肃中医药大学 
摘要点击次数: 1264
全文下载次数: 0
中文摘要:
      免疫疗法作为治疗癌症的一种新兴方法,它利用免疫系统发挥抗肿瘤作用。 但是它只对部分患者有益,目前已被证明患者肠道菌群的不同可能是造成患者疗效差异的原因之一。肠道菌群在形成系统免疫反应中起着重要的作用,可通过先天性免疫和获得性免疫来提高免疫治疗疗效。许多研究已经显示出肠道菌群的成分差异能影响肿瘤对治疗的反应,尤其是免疫检查点抑制剂,有力的证据表明,肠道菌群会影响黑色素瘤、非小细胞肺癌和肾细胞癌的免疫检查点抑制剂反应或耐药性。因此,微生物群的调节可能成为提高基于免疫的癌症疗法疗效的新策略,特别是针对CTLA-4和PD-1途径的检查站封锁方法。本文就近年来有关与肠道菌群在免疫疗法中的作用以及未来可能的干预措施进行综述。
英文摘要:
      As an emerging method of treating cancer, immunotherapy uses the immune system to exert anti-tumor effects. However, it is only beneficial to some patients. It has been proven that the difference in the intestinal flora of patients may be one of the reasons for the difference in efficacy. Intestinal flora plays an important role in the formation of systemic immune response, and can improve the efficacy of immunotherapy through innate immunity and acquired immunity. Many studies have shown that differences in the composition of intestinal flora can affect tumor response to treatment, especially immune checkpoint inhibitors. There is strong evidence that intestinal flora can affect melanoma, non-small cell lung cancer and renal cell carcinoma. The immune checkpoint inhibitor response or resistance. Therefore, the regulation of the microbiota may become a new strategy to improve the efficacy of immune-based cancer therapy, especially the checkpoint blockade method for CTLA-4 and PD-1 pathways. This article reviews the role of intestinal flora in immunotherapy in recent years and possible interventions in the future.
View Fulltext   查看/发表评论  下载PDF阅读器
关闭